Encore Therapeutics Inc. Announces Successful Proof of Concept Study on Meloxicam Depot Injection
10/18/2011 11:15:26 AM
More...
|
Encore Therapeutics Inc. Announces Extended Release Depot Formulation of Ropivacaine Available for License
9/26/2011 10:40:38 AM
More...
|
Progesterone and TBI: Encore Therapeutics Inc. Completes Novel Commercially Enabling Progesterone Formulation for TBI
5/10/2011 10:21:47 AM
More...
|
Encore Therapeutics Inc. Announces Depot Meloxicam Formulation Enabling Local High Drug Dose Delivery
4/4/2011 8:09:37 AM
More...
|
Encore Therapeutics Inc. Demonstrates Proof of Concept for a Long-acting Buprenorphine Depot for Pain and Drug Abuse Therapy (ETI-311)
12/8/2008 12:38:58 PM
More...
|
PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc.
7/2/2008 9:52:11 AM
More...
|
Novel Progesterone Formulation for Stroke and Traumatic Brain Injury Developed by Encore Therapeutics Inc.
6/24/2008 9:42:46 AM
More...
|
Encore Therapeutics Inc. Reports Additional Proof of Concept Results on its Extended Release Ropivacaine Injectable Gel for Postoperative Pain Management
8/2/2007 1:12:26 PM
More...
|
Encore Therapeutics Inc. Reports Efficacy Data On A Long-Acting Local Anesthetic Drug
1/30/2007 12:26:05 PM
More...
|